****

**TABLE OF CONTENTS**

[1. REPORT OVERVIEW 14](#_Toc2509053)

[1.1 Statement of the Report 14](#_Toc2509054)

[1.2 Executive Summary 15](#_Toc2509055)

[2. GENE THERAPY: AN INTRODUCTION 17](#_Toc2509056)

[2.1 Gene Augmentation Therapy 17](#_Toc2509057)

[2.2 Gene Inhibition Therapy 18](#_Toc2509058)

[2.3 Suicide Gene Therapy 18](#_Toc2509059)

[2.4 The Process of Gene Transfer in Gene Therapy 19](#_Toc2509060)

[2.5 Ex Vivo vs. In Vivo Gene Therapies 20](#_Toc2509061)

[2.5.1 Ex Vivo Gene Therapy 20](#_Toc2509062)

[2.5.2 In Vivo Gene Therapy 20](#_Toc2509063)

[2.6 Autologous vs. Allogeneic Gene Therapies 21](#_Toc2509064)

[3. STATUS OF GENE THERAPY INDUSTRY 22](#_Toc2509065)

[3.1 Number of Gene Therapy Companies in the World 22](#_Toc2509066)

[3.2 Gene Therapy Pipeline Volumes, 1995-2018 23](#_Toc2509067)

[3.3 Big Pharma’s Involvement in Gene Therapy Development 24](#_Toc2509068)

[3.4 Number of Gene Therapies Anticipated to be Approved in the Next Three Years 25](#_Toc2509069)

[3.5 Gene Therapy Product Candidates Granted RMAT Designation 26](#_Toc2509070)

[3.5.1 EB-101 27](#_Toc2509071)

[3.5.2 ABO-102 27](#_Toc2509072)

[3.5.3 AT132 27](#_Toc2509073)

[3.5.4 LentiGlobin 27](#_Toc2509074)

[3.5.5 JCAR017 28](#_Toc2509075)

[3.5.6 NSR-RE P1 28](#_Toc2509076)

[3.5.7 P-BCMA-101 28](#_Toc2509077)

[3.5.8 VY-AADC 28](#_Toc2509078)

[3.6 Gene Therapy Companies Active in Neurodegenerative Disorders 29](#_Toc2509079)

[3.6.1 Gene Therapy Developers for Neurodegenerative Disorders 30](#_Toc2509080)

[3.6.2 Neurodegenerative Diseases Addressed by Gene Therapy Studies 31](#_Toc2509081)

[3.6.3 Anticipated Events in Neurodegenerative Space of Gene Therapy 31](#_Toc2509082)

[3.7 Important Events in Gene Therapy Space in 2018 33](#_Toc2509083)

[3.8 Important Gene Therapy Startups 34](#_Toc2509084)

[3.9 Gene Therapy Industry and Global Financings, 2018 35](#_Toc2509085)

[3.10 Corporate Partnerships in 2018 36](#_Toc2509086)

[3.11 Private Placements and Venture Financings in 2018 36](#_Toc2509087)

[3.12 Public Offerings (IPOs & Follow-Ons) in 2018 37](#_Toc2509088)

[4. GENE DELIVERY VEHICLES 38](#_Toc2509089)

[4.1 Viral Vectors 38](#_Toc2509090)

[4.1.1 Physical Properties of Commonly Used Viruses 38](#_Toc2509091)

[4.2 Retrovirus Vectors 39](#_Toc2509092)

[4.3 Adenovirus Vectors 39](#_Toc2509093)

[4.4 Herpes Simplex Viral Vectors 40](#_Toc2509094)

[4.5 Lentiviral Vectors 40](#_Toc2509095)

[4.5.1 Utilization of Lentivirus Vectors by Disease Type in Clinical Trials 41](#_Toc2509096)

[4.5.2 Companies Developing Lentivirus Vectors 41](#_Toc2509097)

[4.6 Adeno-Associated Virus Vectors 42](#_Toc2509098)

[4.6.1 Types of Diseases in Clinical Trials using AAV 43](#_Toc2509099)

[4.6.2 Genes Transduced by AAV for Specific Diseases 44](#_Toc2509100)

[4.6.3 Companies Developing AAV Vectors 44](#_Toc2509101)

[4.7 The Predominantly Used Viral Vectors 45](#_Toc2509102)

[4.8 Non-Viral Vectors 46](#_Toc2509103)

[4.8.1 Microinjection 46](#_Toc2509104)

[4.8.2 Particle Bombardment 46](#_Toc2509105)

[4.8.3 Laser Irradiation 47](#_Toc2509106)

[4.8.4 Electroporation 47](#_Toc2509107)

[4.8.5 Magnetofection 48](#_Toc2509108)

[4.8.6 Sonoporation 48](#_Toc2509109)

[5. GENE THERAPY CLINICAL TRIALS 49](#_Toc2509110)

[5.1 Gene Therapy Clinical Trials by Geography 50](#_Toc2509111)

[5.2 Diseases Targeted by Gene Therapy Clinical Trials 51](#_Toc2509112)

[5.3 Gene Types Transduced in Clinical Trials 52](#_Toc2509113)

[5.4 Vectors used in Gene Therapy Clinical Trials 53](#_Toc2509114)

[5.5 Gene Therapy Clinical Trials for Neurodegenerative Indications by Type 54](#_Toc2509115)

[5.6 Domination of Oncology in Gene Therapy Development 55](#_Toc2509116)

[5.8 Anticipated Clinical Events in Gene Therapy Space, 2019/2020 57](#_Toc2509117)

[6. CHIMERIC ANTIGEN RECEPTOR T CELL (CAR-T CELL) THERAPY 64](#_Toc2509118)

[6.1 Geographical Distribution of CAR-T Cell Therapy Companies 64](#_Toc2509119)

[6.2 Select Events in CAR-T Space in 2018 66](#_Toc2509120)

[6.3 Timeline of CAR-T Therapy Development 66](#_Toc2509121)

[6.4 CAR-T Manufacturing Processes 67](#_Toc2509122)

[6.4.1 Manufacturing of Autologous CAR-T Cells 67](#_Toc2509123)

[6.4.1.1 Source of T Cells 68](#_Toc2509124)

[6.4.1.2 T Cell Activation 68](#_Toc2509125)

[6.4.1.3 Genetic Modification of T Cells 70](#_Toc2509126)

[6.4.1.4 Expansion of CAR-T Cells 71](#_Toc2509127)

[6.4.2 Manufacturing of Allogeneic CAR-T Cells 71](#_Toc2509128)

[6.5 Structure of a CAR-T Cell 72](#_Toc2509129)

[6.5.1 First Generation CAR-T Cells 73](#_Toc2509130)

[6.5.2 Second Generation CAR-T Cells 74](#_Toc2509131)

[6.5.3 Third Generation CAR-T Cells 75](#_Toc2509132)

[6.5.4 Fourth Generation CAR-T Cells 75](#_Toc2509133)

[6.6 CAR-T Cells: Mechanism of Action 76](#_Toc2509134)

[6.7 Common Designs of CAR-T Constructs 77](#_Toc2509135)

[6.8 Transfection by Vectors 78](#_Toc2509136)

[6.9 CAR-T Cell Targets in Solid Malignancies 78](#_Toc2509137)

[6.10 Target Diseases for CAR-T Cell Therapy 79](#_Toc2509138)

[7. CAR-T PATENT LANDSCAPE 80](#_Toc2509139)

[7.1 Number of CAR-T Patents, 2013-2018 80](#_Toc2509140)

[7.2 CAR-T Patent Types 80](#_Toc2509141)

[7.3 A Brief Snapshot of CAR-T Patent Landscape 82](#_Toc2509142)

[7.3.1 Patents for Anti-CD19 CAR-T 82](#_Toc2509143)

[7.3.2 Patents for Anti-BCMA CAR-T 82](#_Toc2509144)

[7.3.3 Patents for Regulatable CAR-T 83](#_Toc2509145)

[7.4 CAR-T Patents for Solid Tumors 83](#_Toc2509146)

[7.5 Major CAR-T Patent Applicants 84](#_Toc2509147)

[8. THE CAR-T CLINICAL TRIALS LANDSCAPE 85](#_Toc2509148)

[8.1 The Surge in Number of CAR-T Clinical Trials 85](#_Toc2509149)

[8.2 Percentage of CAR-T Clinical Trials by Target Antigen 86](#_Toc2509150)

[8.3 Research Focus on CAR-T Trials by Indication 87](#_Toc2509151)

[8.4 CAR-T Projects with Commercial Licensees 88](#_Toc2509152)

[8.5 CAR-T Projects with Sole Involvement from Academia 89](#_Toc2509153)

[8.6 Anti-CD19 Projects 90](#_Toc2509154)

[8.7 CAR-T Studies in Multiple Myeloma (MM) and Acute Myeloid Leukemia (AML) 92](#_Toc2509155)

[8.8 CAR-T Projects in Solid Tumors 93](#_Toc2509156)

[8.9 CAR-T Projects using mRNA Electroporation for Gene Insertion 95](#_Toc2509157)

[8.10 CAR-T Projects using Suicide Genes 95](#_Toc2509158)

[8.11 Early-Stage CAR-T Assets 96](#_Toc2509159)

[8.12 CAR-T Clinical Trials in China 97](#_Toc2509160)

[8.12.1 CD19-Directed CAR-T Projects in China 98](#_Toc2509161)

[8.12.2 Chinese CAR-T Projects Targeting Non-CD19 Antigens 100](#_Toc2509162)

[8.12.3 Chinese CAR-T Projects in Solid Tumors 100](#_Toc2509163)

[8.12.4 Chinese Projects using Fourth Generation CAR-T Constructs 102](#_Toc2509164)

[8.12.5 Clinical-Stage CAR-T Projects in China 102](#_Toc2509165)

[8.13 Anticipated Developments in CAR-T Space, 2019-2020 104](#_Toc2509166)

[9. MEDICAL FACILITIES OFFERING CAR-T THERAPIES 106](#_Toc2509167)

[9.1 U.S. Hospitals Offering CAR-T Therapies 106](#_Toc2509168)

[9.2 Facilities Offering CAR-T Therapies in Germany 108](#_Toc2509169)

[9.3 Hospitals Offering CAR-T Therapies in the U.K. 108](#_Toc2509170)

[10. GENE THERAPY PRODUCTS 110](#_Toc2509171)

[I0.1 Gendicine 112](#_Toc2509172)

[10.2 Oncorine 113](#_Toc2509173)

[10.3 Rexin-G 113](#_Toc2509174)

[10.4 Neovasculgen (vascular endothelial growth factor gene) 114](#_Toc2509175)

[10.5 Imlygic (talimogene laherparepvec) 114](#_Toc2509176)

[10.6 Strimvelis (autologous CD34+ enriched cells) 115](#_Toc2509177)

[10.7 Zalmoxis 116](#_Toc2509178)

[10.8 Invossa (tonogenchoncel-L) 116](#_Toc2509179)

[10.9 Kymriah (tisagenlecleucel-t) 117](#_Toc2509180)

[10.9.1 Overall Remission Rates in Patients Treated with Kymriah 118](#_Toc2509181)

[10.9.2 Overall Event-Free Survival Rate with Kymriah 118](#_Toc2509182)

[10.10 Yescarta (axicabtagene ciloleucel) 119](#_Toc2509183)

[10.10.1 Effectiveness of Yescarta 120](#_Toc2509184)

[10.10.2 Clinical Benefits of Yescarta 120](#_Toc2509185)

[10.10.3 Objective Response Rates (ORR) Reported for Yescarta 121](#_Toc2509186)

[10.10.4 Complete Remission Rate (CRR) for Yescarta 121](#_Toc2509187)

[10.11 Luxturna (voretigene neparvovec-rzyl) 122](#_Toc2509188)

[10.12 Patient Impact of the Three Products Approved in the U.S. in 2017 123](#_Toc2509189)

[10.13 Anticipated Number of Product Launches between 2018 and 2030 124](#_Toc2509190)

[10.14 Number of Gene Therapies Available in Eight Major Markets as of January 2019 125](#_Toc2509191)

[10.15 Five Forthcoming Gene Therapies 126](#_Toc2509192)

[11. PRICING AND PAYMENT MODELS FOR GENE THERAPIES 128](#_Toc2509193)

[11.1 CMS and Payments for Kymriah and Yescarta 129](#_Toc2509194)

[11.2 Kymriah’s Outcome-Based Contracts (OBCs) 129](#_Toc2509195)

[11.3 Luxturna’s Installment Payment Plan 130](#_Toc2509196)

[11.4 Other Suggested Payment Options for Gene Therapies 130](#_Toc2509197)

[12. MANUFACTURING OF CELLS AND VIRUS VECTORS 131](#_Toc2509198)

[12.1 Cost of Manufacture of Cells and Virus Vectors 132](#_Toc2509199)

[12.2 Cost of Manufacture in a Partially-Automated Facility 133](#_Toc2509200)

[12.3 Cost of Manufacture in a Fully-Automated Facility 134](#_Toc2509201)

[12.4 Net Present Cost (NPC) of the Three Methods 135](#_Toc2509202)

[12.5 In-House Gene Therapy Manufacturing Capabilities 135](#_Toc2509203)

[12.6 External Gene Therapy Manufacturing 136](#_Toc2509204)

[12.7 Manufacturing Capacity in North America 137](#_Toc2509205)

[12.8 Manufacturing Capacity in Europe 139](#_Toc2509206)

[13. CMOs & CDMOs 142](#_Toc2509207)

[13.1 Appropriate Phase for Outsourcing 143](#_Toc2509208)

[13.2 Important Points Considered While Selecting a CDMO 144](#_Toc2509209)

[13.3 In-House vs. Outsourcing 145](#_Toc2509210)

[13.4 Number of CMPs and CDMOs in Europe 146](#_Toc2509211)

[13.5 Projected Growth of Outsourcing Market 146](#_Toc2509212)

[13.6 Projected Growth of Manufacturing Capacity 147](#_Toc2509213)

[14. MARKET ANALYSIS 148](#_Toc2509214)

[14.1 Global Market for Gene Therapy by Product Category 149](#_Toc2509215)

[14.2 Competitive Landscape in Gene-Modified Cell Therapy Products 151](#_Toc2509216)

[14.3 Estimated Sales of Top Ten Clinical-Stage Gene Therapy Projects 151](#_Toc2509217)

[14.3.1 LentiGlobin to be on Top among the Top Ten 151](#_Toc2509218)

[14.4 Global Market for Viral Vector and Plasmid DNA Manufacturing 153](#_Toc2509219)

[14.5 Top Nine Assets of Gene Therapy between 2018 and 2024 155](#_Toc2509220)

[14.5.1 Zolgensma (AVXS-101) 156](#_Toc2509221)

[14.5.2 JCAR017, bb2121 156](#_Toc2509222)

[14.5.3 Lentiglobin (BB305) 156](#_Toc2509223)

[14.5.4 Valoctocogene roxaparvovec 156](#_Toc2509224)

[14.5.5 ABO-102 157](#_Toc2509225)

[14.5.6 Tabelecleucel 157](#_Toc2509226)

[14.6 Net Present Value (NPV) of Select Gene Therapy Product Candidates 157](#_Toc2509227)

[15. COMPANY PROFILES 159](#_Toc2509228)

[15.1 4D Molecular Therapeutics, LLC 159](#_Toc2509229)

[15.1.1 Key Capabilities 159](#_Toc2509230)

[15.2 Abeona Therapeutics, Inc. 161](#_Toc2509231)

[15.3 Adaptimmune Therapeutics, plc 162](#_Toc2509232)

[15.4 Advanced Bioscience Laboratories, Inc. 163](#_Toc2509233)

[15.4.1 Biomanufacturing Services 163](#_Toc2509234)

[15.4.2 Manufacturing of Virus-Based Products 163](#_Toc2509235)

[15.4.3 Manufacturing of Protein-Based Products 163](#_Toc2509236)

[15.4.4 Asceptic Filling Services 164](#_Toc2509237)

[15.4.5 Immunology and Biomarker Testing 164](#_Toc2509238)

[15.4.6 Contract Research Assays 164](#_Toc2509239)

[15.4.7 Clinical Immunology Solutions 165](#_Toc2509240)

[15.4.8 Preclinical Solutions 165](#_Toc2509241)

[15.4.9 In vivo and ex vivo Preclinical Studies 165](#_Toc2509242)

[15.4.10 Product Development Solutions 165](#_Toc2509243)

[15.4.11 Government Partnering 165](#_Toc2509244)

[15.4.12 Translational Product Development 166](#_Toc2509245)

[15.5 Adverum Biotechnologies, Inc. 167](#_Toc2509246)

[15.6 Akouos, Inc. 168](#_Toc2509247)

[15.7 Aldevron, LLC 169](#_Toc2509248)

[15.7.1 Services 169](#_Toc2509249)

[15.8 Allogene Therapeutics, Inc. 170](#_Toc2509250)

[15.9 Ambys Medicines, Inc. 171](#_Toc2509251)

[15.10 American Gene Technologies International, Inc. 172](#_Toc2509252)

[15.11 Amgen, Inc. 173](#_Toc2509253)

[15.11.1 Imlygic (talimogene laherparepvec) 173](#_Toc2509254)

[15.12 Amicus Therapeutics, Inc. 174](#_Toc2509255)

[15.13 AskBio 175](#_Toc2509256)

[15.14 Audentes Therapeutics, Inc. 176](#_Toc2509257)

[15.14.1 AT132 176](#_Toc2509258)

[15.14.2 AT342 176](#_Toc2509259)

[15.14.3 AT982 177](#_Toc2509260)

[15.14.4 AT307 177](#_Toc2509261)

[15.15 AveXis, Inc. 178](#_Toc2509262)

[15.15.1 AVXS-101 178](#_Toc2509263)

[15.16 AVROBIO, INC. 179](#_Toc2509264)

[15.16.1 AVR-RD-01 179](#_Toc2509265)

[15.16.2 AVR-RD-02 179](#_Toc2509266)

[15.16.3 AVR-RD-03 180](#_Toc2509267)

[15.16.4 AVR-RD-04 180](#_Toc2509268)

[15.17 Benitec Biopharma Ltd. 181](#_Toc2509269)

[15.18 Bioverativ, Inc. 182](#_Toc2509270)

[15.19 bluebird bio, Inc. 183](#_Toc2509271)

[15.19.1 Partnering 183](#_Toc2509272)

[15.19.2 Current Partners 184](#_Toc2509273)

[15.20 BlueRock Therapeutics 185](#_Toc2509274)

[15.20.1 BlueRock’s Pipeline 185](#_Toc2509275)

[15.21 Brammer Bio, LLC 186](#_Toc2509276)

[15.21.1 Services 186](#_Toc2509277)

[15.21.2 Product Development 186](#_Toc2509278)

[15.21.3 Gene Therapy Manufacturing 186](#_Toc2509279)

[15.21.4 Viral Vectors 187](#_Toc2509280)

[15.22 Carina Biotech 188](#_Toc2509281)

[15.22.1 CNA1003 188](#_Toc2509282)

[15.23 CARsgen Therapeutics, Ltd. 189](#_Toc2509283)

[15.24 Casebia Therapeutics 190](#_Toc2509284)

[15.25 Celyad SA 191](#_Toc2509285)

[15.26 Cevec Pharmaceuticals GmbH 192](#_Toc2509286)

[15.26.1 Services 192](#_Toc2509287)

[15.27 CombiGene AB 193](#_Toc2509288)

[15.27.1 Epilepsy Project 193](#_Toc2509289)

[15.28 CRISPR Therapeutics AG 194](#_Toc2509290)

[15.29 Delphi Genetics S.A. 195](#_Toc2509291)

[15.29.1 Services 195](#_Toc2509292)

[15.30 DNAlite Therapeutics, Inc. 196](#_Toc2509293)

[15.31 Editas Medicine, Inc. 197](#_Toc2509294)

[15.32 Elixirgen Therapeutics, LLC 198](#_Toc2509295)

[15.33 Fibrocell Technologies, Inc. 199](#_Toc2509296)

[15.33.1 Fibrocell’s Pipeline 199](#_Toc2509297)

[15.34 FinVector Vision Therapies Oy 200](#_Toc2509298)

[15.34.1 Services 200](#_Toc2509299)

[15.35 Freeline Therapeutics, Ltd. 201](#_Toc2509300)

[15.36 Gemini Therapeutics, Inc. 202](#_Toc2509301)

[15.37 GEG Tech 203](#_Toc2509302)

[15.37.1 Lenti-ONE Vectors 203](#_Toc2509303)

[15.38 Genethon 204](#_Toc2509304)

[15.39 Generation Bio Co. 205](#_Toc2509305)

[15.40 Homology Medicines, Inc. 206](#_Toc2509306)

[15.40.1 Gene Editing Platform 206](#_Toc2509307)

[15.41 Horama SAS 207](#_Toc2509308)

[15.42 Intellia Therapeutics Inc. 208](#_Toc2509309)

[15.43 Kite Pharma, Inc. 209](#_Toc2509310)

[15.43.1 Yescarta 209](#_Toc2509311)

[15.44 Kolon Lifesciences, Inc. 210](#_Toc2509312)

[15.44.1 Invossa-K inj. 210](#_Toc2509313)

[15.45 Krystal Biotech, Inc. 211](#_Toc2509314)

[15.46 LakePharma 212](#_Toc2509315)

[15.46.1 Viral Vector Services 212](#_Toc2509316)

[15.47 Lonza Group, Ltd. 213](#_Toc2509317)

[15.47.1 Custom Development and Manufacturing 213](#_Toc2509318)

[15.48 Lysogene S.A. 215](#_Toc2509319)

[15.48.1 MPS IIIA 215](#_Toc2509320)

[15.48.2 GM1 Gangliosidosis 215](#_Toc2509321)

[15.49 MeiraGTx Holdings plc 216](#_Toc2509322)

[15.49.1 Meira’s Pipeline 216](#_Toc2509323)

[15.49.1.1 AAV-CNGB3 217](#_Toc2509324)

[15.49.1.2 AAV-RPE65 217](#_Toc2509325)

[15.49.1.3 AAV-RPGR 217](#_Toc2509326)

[15.49.1.4 AAV-AQP1 217](#_Toc2509327)

[15.49.1.5 AAV-GAD 218](#_Toc2509328)

[15.49.1.6 AAV-UPF1 218](#_Toc2509329)

[15.50 MolMed S.p.A 219](#_Toc2509330)

[15.50.1 MolMed’s Clinical Trial Programs 219](#_Toc2509331)

[15.50.2 MolMed’s GMP Solutions 219](#_Toc2509332)

[15.51 Mustang Bio, Inc. 221](#_Toc2509333)

[15.51.1 MB-101 221](#_Toc2509334)

[15.51.2 MB-102 222](#_Toc2509335)

[15.51.3 MB-103 222](#_Toc2509336)

[15.51.4 MB-104 222](#_Toc2509337)

[15.51.5 MB-105 223](#_Toc2509338)

[15.51.6 MB-106 223](#_Toc2509339)

[15.51.7 MB-107 223](#_Toc2509340)

[15.52 Myonexus Therapeutics, Inc. 224](#_Toc2509341)

[15.53 Nightstar Therapeutics plc 225](#_Toc2509342)

[15.54 Novartis AG 226](#_Toc2509343)

[15.54.1 Kymriah 226](#_Toc2509344)

[15.55 Orchard Therapeutics plc 227](#_Toc2509345)

[15.55.1 Strimvelis 227](#_Toc2509346)

[15.55.2 OTL-101 227](#_Toc2509347)

[15.55.3 OTL-102 228](#_Toc2509348)

[15.55.4 OTL-103 228](#_Toc2509349)

[15.55.5 OTL-200 228](#_Toc2509350)

[15.55.6 OTL-201 228](#_Toc2509351)

[15.55.7 OTL-202 229](#_Toc2509352)

[15.55.8 OTL-300 229](#_Toc2509353)

[15.56 OxfordBioMedica plc 230](#_Toc2509354)

[15.56.1 Oxford BioMedica’s Partnering Activities 230](#_Toc2509355)

[15.57 Oxford Genetics, Ltd. 232](#_Toc2509356)

[15.57.1 Scalable AAV Custom Solutions 232](#_Toc2509357)

[15.58 Paragon Bioservices, Inc. 233](#_Toc2509358)

[15.58.1 Services 233](#_Toc2509359)

[15.59 Posedia Therapeutics, Inc. 234](#_Toc2509360)

[15.60 Precision BioSciences, Inc. 235](#_Toc2509361)

[15.60.1 ARCUS Genome Editing Platform 235](#_Toc2509362)

[15.61 Prevail Therapeutics, Inc. 236](#_Toc2509363)

[15.61.1 Prevail’s Focus 236](#_Toc2509364)

[15.62 PTC Therapeutics, Inc. 237](#_Toc2509365)

[15.63 Quethera, Ltd. 238](#_Toc2509366)

[15.63.1 Technology 238](#_Toc2509367)

[15.64 REGENXBIO, INC. 239](#_Toc2509368)

[15.64.1 NAV Technology 239](#_Toc2509369)

[15.64.2 Therapeutic Programs 239](#_Toc2509370)

[15.64.3 Product Candidates 240](#_Toc2509371)

[15.64.3.1 RGX-314 240](#_Toc2509372)

[15.64.3.2 RGX-501 240](#_Toc2509373)

[15.64.3.3 RGX-111 240](#_Toc2509374)

[15.64.3.4 RGX-121 240](#_Toc2509375)

[15.64.3.5 RGX-181 241](#_Toc2509376)

[15.64.4 Partnerships and Licensing 241](#_Toc2509377)

[15.65 Rocket Pharmaceuticals, Inc. 243](#_Toc2509378)

[15.66 Sangamo Therapeutics, Inc. 244](#_Toc2509379)

[15.67 Sarepta Therapeutics, Inc. 245](#_Toc2509380)

[15.68 Sibiono GeneTech Co. Ltd. 247](#_Toc2509381)

[15.68.1 Gendicine 247](#_Toc2509382)

[15.69 Sirion Biotech, GmbH 248](#_Toc2509383)

[15.69.1 Viral Vectors 248](#_Toc2509384)

[15.69.2 Technologies 248](#_Toc2509385)

[15.70 Solid Biosciences, Inc. 249](#_Toc2509386)

[15.70.1 SGT-001 249](#_Toc2509387)

[15.71 Spark Therapeutics, Inc. 250](#_Toc2509388)

[15.71.1 Luxturna 250](#_Toc2509389)

[15.71.2 Spark Therapeutics’ Pipeline 251](#_Toc2509390)

[15.72 Synpromics, Ltd. 252](#_Toc2509391)

[15.72.1 Technology 252](#_Toc2509392)

[15.72.2 PromPT 252](#_Toc2509393)

[15.73 Takara Bio, Inc. 253](#_Toc2509394)

[15.73.1 Services & Support 253](#_Toc2509395)

[15.74 The Cell and Gene Therapy Catapult 254](#_Toc2509396)

[15.74.1 Catapult’s Industrialization Team 254](#_Toc2509397)

[15.74.2 Catapult’s Manufacturing Center at Stevenage 254](#_Toc2509398)

[15.74.3 Catapult’s Regulatory Team 254](#_Toc2509399)

[15.75 Translate Bio, Inc. 255](#_Toc2509400)

[15.76 Ultragenyx Pharmaceutical, Inc. 256](#_Toc2509401)

[15.76.1 DTX301 256](#_Toc2509402)

[15.76.2 DTX401 256](#_Toc2509403)

[15.77 uniQure N.V. 257](#_Toc2509404)

[15.78 Vybion, Inc. 258](#_Toc2509405)

[15.78.1 INT41 258](#_Toc2509406)

[15.79 Vigene Biosciences 259](#_Toc2509407)

[15.80 Virovek, Inc. 260](#_Toc2509408)

[15.80.1 Custom-Made AAVs 260](#_Toc2509409)

[15.81 Vivebiotech SL 261](#_Toc2509410)

[15.81.1 Lentisoma Technology 261](#_Toc2509411)

[15.81.2 Services 261](#_Toc2509412)

[15.82 Vivet Therapeutics 262](#_Toc2509413)

[15.82.1 Vivet’s Approach 262](#_Toc2509414)

[15.83 Voyager Therapeutics, Inc. 263](#_Toc2509415)

**INDEX OF FIGURES**

[FIGURE 2.1: Diagrammatic Representation of Gene Augmentation Therapy 17](#_Toc2509471)

[FIGURE 2.2: Schematic Representation of Gene Inhibition Therapy 18](#_Toc2509472)

[FIGURE 2.3: Diagrammatic Representation of Suicide Gene Therapy 19](#_Toc2509473)

[FIGURE 2.4: Illustration Showing the Viral Vector Transferring Gene into the Patient’s Cell 19](#_Toc2509474)

[FIGURE 2.5: Autologous and Allogeneic Gene Therapies 21](#_Toc2509475)

[FIGURE 3.1: Number of Gene and Gene-Based Medicine Companies by Geography 23](#_Toc2509476)

[FIGURE 3.2: Gene Therapy Pipeline Volumes, 1995 to Present 24](#_Toc2509477)

[FIGURE 3.3: Minor Role Played by Big Pharma in Gene Therapy 25](#_Toc2509478)

[FIGURE 3.4: Number of Gene Therapies to Gain FDA Approval by 2022 26](#_Toc2509479)

[FIGURE 3.5: Gene Therapy Companies in Neurodegenerative Disorders by Geography 29](#_Toc2509480)

[FIGURE 3.6: Gene Therapy Industry and Global Financings 35](#_Toc2509481)

[FIGURE 4.1: Utilization of Lentivirus Vectors by Disease Type in Clinical Trials 41](#_Toc2509482)

[FIGURE 4.2: Companies Developing Lentivirus Vectors 42](#_Toc2509483)

[FIGURE 4.3: Types of Diseases in Clinical Trials using AAV 43](#_Toc2509484)

[FIGURE 4.4: Companies Developing AAV Vectors 45](#_Toc2509485)

[FIGURE 5.1: Number of Gene Therapy Clinical Trials by Year 49](#_Toc2509486)

[FIGURE 5.2: Gene Therapy Clinical Trials by Geography, 2018 50](#_Toc2509487)

[FIGURE 5.3: Diseases Targeted by Gene Therapy 51](#_Toc2509488)

[FIGURE 5.4: Gene Types Transduced in Clinical Trials 52](#_Toc2509489)

[FIGURE 5.6: Vectors used in Gene Therapy Clinical Trials 53](#_Toc2509490)

[FIGURE 5.7: Gene Therapy Clinical Trials for Neurodegenerative Indications by Type, 2018 54](#_Toc2509491)

[FIGURE 5.8: Domination of Oncology in Gene Therapy Development 55](#_Toc2509492)

[FIGURE 5.9: Dominance of Viral Vectors in Gene Therapy Drug Development 56](#_Toc2509493)

[FIGURE 6.1: Geographical Distribution of CAR-T Cell Therapy Companies 65](#_Toc2509494)

[FIGURE 6.3: The Process of CAR-T Cell Manufacturing 68](#_Toc2509496)

[FIGURE 6.4: Building a CAR-T Cell and its Binding to Tumor Antigen 73](#_Toc2509497)

[FIGURE 6.5: First Generation CAR-T Cells 73](#_Toc2509498)

[FIGURE 6.6: Second Generation CAR-T Cells 74](#_Toc2509499)

[FIGURE 6.7: Third Generation CAR-T Cells 75](#_Toc2509500)

[FIGURE 6.8: Fourth Generation CAR-T Cells 76](#_Toc2509501)

[FIGURE 6.9: Recognition and Killing of Cancer Cells by CAR-T Cells 77](#_Toc2509502)

[FIGURE 6.10: Most Frequent CAR-T Targets in Solid Malignancies 79](#_Toc2509503)

[FIGURE 7.1: Number of CAR-T Patents by Year 80](#_Toc2509504)

[FIGURE 7.1: Major CAR-T Patent Applicants 84](#_Toc2509505)

[FIGURE 8.1: The Surge in Number of CAR-T Clinical Trials, 2007-2018 85](#_Toc2509506)

[FIGURE 8.2: Percentage of CAR-T Clinical Trials by Target Antigen 86](#_Toc2509507)

[FIGURE 8.3: Research Focus on CAR-T Trials by Indication 87](#_Toc2509508)

[FIGURE 8.4: CAR-T Cells Targeting Antigens on Solid Tumors 93](#_Toc2509509)

[FIGURE 10.1: Anticipated Number of Product Launches between 2018 and 2030 125](#_Toc2509510)

[FIGURE 12.1: Expenditure Categories in Cell Manufacturing 131](#_Toc2509511)

[FIGURE 12.2: The Impact of Head Count on Labor Cost 132](#_Toc2509512)

[FIGURE 12.3: Cost of Manufacture in a Partially-Automated Facility 133](#_Toc2509513)

[FIGURE 12.4: Cost of Manufacture in a Fully-Automated Facility 134](#_Toc2509514)

[FIGURE 12.5: Net Present Cost (NPC) of the Three Methods 135](#_Toc2509515)

[FIGURE 13.1: Appropriate Phase for Outsourcing 143](#_Toc2509516)

[FIGURE 13.2: Important Points Considered While Fixing a CDMO 144](#_Toc2509517)

[FIGURE 13.3: Share of In-House and Outsourcing 145](#_Toc2509518)

[FIGURE 13.4: Number of CMPs and CDMOs in Europe 146](#_Toc2509519)

[FIGURE 13.5: Projected Growth of Outsourcing Market, 2018-2025 147](#_Toc2509520)

[FIGURE 14.1: Global Market for Gene Therapy Products, 2018-2025 149](#_Toc2509522)

[FIGURE 14.2: Global Market for Gene Therapy by Product Category through 2025 150](#_Toc2509523)

[FIGURE 14.3: Vector and Plasmid DNA Manufacturing Market by Geography through 2025 154](#_Toc2509524)

**INDEX OF TABLES**

[TABLE 3.1: Number of Gene Therapy Companies by Geography 22](#_Toc2509687)

[TABLE 3.2: Gene Therapy Product Candidates Granted RMAT Designation 26](#_Toc2509688)

[TABLE 3.3: Gene Therapy Companies in Neurodegenerative Disorders by Geography 29](#_Toc2509689)

[TABLE 3.4: Gene Therapy Developers for Neurodegenerative Disorders 30](#_Toc2509690)

[TABLE 3.5: Neurodegenerative Diseases Addressed by Gene Therapy Studies 31](#_Toc2509691)

[TABLE 3.6: Select Anticipated Events in Neurodegenerative Space of Gene Therapy 32](#_Toc2509692)

[TABLE 3.7: Select Events in Gene Therapy Space 33](#_Toc2509693)

[TABLE 3.8: Important Gene Therapy Startups 34](#_Toc2509694)

[TABLE 3.9: Gene Therapy Industry and Global Financings 35](#_Toc2509695)

[TABLE 3.10: Corporate Partnerships in 2018 36](#_Toc2509696)

[TABLE 3.11: Private Placements and Venture Financings 37](#_Toc2509697)

[TABLE 3.12: Public Offerings (IPOs & Follow-Ons) 37](#_Toc2509698)

[TABLE 4.2: Retroviral Vectors: A Snapshot 39](#_Toc2509700)

[TABLE 4.3: Adenovirus Vectors: A Snapshot 39](#_Toc2509701)

[TABLE 4.4: Herpes Simplex Viral Vectors: A Snapshot 40](#_Toc2509702)

[TABLE 4.5: Lentivirus Vectors: A Snapshot 40](#_Toc2509703)

[TABLE 4.6: Adeno-Associated Virus Vectors: A Snapshot 42](#_Toc2509704)

[TABLE 4.7: Genes Transduced by AAV for Specific Diseases 44](#_Toc2509705)

[TABLE 4.8: The Predominantly Used Viral Vectors 45](#_Toc2509706)

[TABLE 4.9: Microinjection Method of Gene Delivery 46](#_Toc2509707)

[TABLE 4.10: Particle Bombardment Method of Gene Delivery 46](#_Toc2509708)

[TABLE 4.11: Laser Irradiation Method of Gene Delivery 47](#_Toc2509709)

[TABLE 4.12: Electroporation Method of Gene Delivery 47](#_Toc2509710)

[TABLE 4.13: Magnetofection Method of Gene Delivery 48](#_Toc2509711)

[TABLE 4.14: Sonoporation Method of Gene Delivery 48](#_Toc2509712)

[TABLE 5.1: Number of Gene Therapy Clinical Trials 49](#_Toc2509713)

[TABLE 5.2: Gene Therapy Clinical Trials by Geography 50](#_Toc2509714)

[TABLE 5.3: Diseases Targeted by Gene Therapy 51](#_Toc2509715)

[TABLE 5.4: Gene Types Transduced in Clinical Trials 52](#_Toc2509716)

[TABLE 5.6: Vectors used in Gene Therapy Clinical Trials 53](#_Toc2509717)

[TABLE 5.7: Gene Therapy Clinical Trials for Neurodegenerative Indications by Type 54](#_Toc2509718)

[TABLE 5.8: Domination of Oncology in Gene Therapy Development 55](#_Toc2509719)

[TABLE 5.9: Select Anticipated Clinical Data and Events in 2019/2020 57](#_Toc2509720)

[TABLE 6.1: Geographical Distribution of CAR-T Cell Therapy Companies 65](#_Toc2509727)

[TABLE 6.2: Select Events in CAR-T Space 66](#_Toc2509728)

[TABLE 6.3: Timeline of CAR-T Cell Therapy Development 67](#_Toc2509729)

[TABLE 6.4: Different Types of CAR-T Constructs, Corresponding Antigens and Indications 77](#_Toc2509730)

[TABLE 6.5: Most Frequent CAR-T Targets in Solid Malignancies 78](#_Toc2509731)

[TABLE 6.6: Target Diseases and Target Antigens for CAR-T Cell Therapy 79](#_Toc2509732)

[TABLE 7.1: Major CAR-T Patent Holders 81](#_Toc2509733)

[TABLE 7.2: Select List of CAR-T Patents 83](#_Toc2509734)

[TABLE 7.3: Major CAR-T Patent Applicants 84](#_Toc2509735)

[TABLE 8.1: The Surge in Number of CAR-T Clinical Trials 85](#_Toc2509736)

[TABLE 8.2: Percentage of CAR-T Clinical Trials by Target Antigen 86](#_Toc2509737)

[TABLE 8.3: Research Focus on CAR-T Trials by Indication 87](#_Toc2509738)

[TABLE 8.4: CAR-T Projects with Commercial Licensees 88](#_Toc2509739)

[TABLE 8.4: (CONTINUED) 89](#_Toc2509740)

[TABLE 8.5: CAR-T Projects with Sole Involvement from Academia 90](#_Toc2509741)

[TABLE 8.6: Anti-CD19 Projects 91](#_Toc2509742)

[TABLE 8.7: CAR-T Studies in Multiple Myeloma (MM) and Acute Myeloid Leukemia (AML) 92](#_Toc2509743)

[TABLE 8.8: CAR-T Projects in Solid Tumors 94](#_Toc2509744)

[TABLE 8.9: CAR-T Projects using mRNA Electroporation for Gene Insertion 95](#_Toc2509745)

[TABLE 8.10: CAR-T Projects using Suicide Genes 96](#_Toc2509746)

[TABLE 8.11: Early-Stage CAR-T Assets 97](#_Toc2509747)

[TABLE 8.12: Distribution of CAR-T Clinical Trials in China 97](#_Toc2509748)

[TABLE 8.13: CD19-Directed CAR-T Projects in China 99](#_Toc2509749)

[TABLE 8.14: Chinese CAR-T Projects Targeting Non-CD19 Antigens 100](#_Toc2509750)

[TABLE 8.15: Select Chinese CAR-T Projects in Solid Tumors 101](#_Toc2509751)

[TABLE 8.16: Chinese Projects using Fourth Generation CAR-T Constructs 102](#_Toc2509752)

[TABLE 8.17: Clinical-Stage CAR-T Projects in China 103](#_Toc2509753)

[TABLE 8.18: Anticipated Developments in CAR-T Space 104](#_Toc2509754)

[TABLE 8.18: (CONTINUED) 105](#_Toc2509755)

[TABLE 9.1: U.S. Medical Facilities Offering CAR-T Therapy 106](#_Toc2509756)

[TABLE 9.1: (CONTINUED) 107](#_Toc2509757)

[TABLE 9.1: (CONTINUED) 108](#_Toc2509758)

[TABLE 9.2: Facilities Offering CAR-T Therapies in the U.K. 109](#_Toc2509759)

[TABLE 10.1: Approved Gene Therapy Products 110](#_Toc2509760)

[TABLE 10.1: (CONTINUED) 111](#_Toc2509761)

[TABLE 10.1: (CONTINUED) 112](#_Toc2509762)

[TABLE 10.2: Overall Remission Rates in Patients Treated with Kymriah 118](#_Toc2509763)

[TABLE 10.3: Event-Free Survival at Six and 12 Months in ALL Patients 119](#_Toc2509764)

[TABLE 10.4: Yescarta’s Timeline of Development 120](#_Toc2509765)

[TABLE 10.5: Objective Response Rates (ORR) Reported for Yescarta 121](#_Toc2509766)

[TABLE 10.6: CRR for Yescarta Compared with CRR of SCHOLAR-1 Trial 121](#_Toc2509767)

[TABLE 10.7: The Development Timeline of Luxturna 123](#_Toc2509768)

[TABLE 10.8: Patient Impact of the Three Products Approved in the U.S. in 2017 124](#_Toc2509769)

[TABLE 10.9: Number of Gene Therapies in Eight Major Markets a 126](#_Toc2509770)

[TABLE 10.10: Details of the Five Forthcoming Gene Therapies 127](#_Toc2509771)

[TABLE 11.1: Cost and Market Size for Organ Transplants in the U.S. 128](#_Toc2509772)

[TABLE 11.2: Cost and Market Size for Three Gene Therapies in the U.S. 129](#_Toc2509773)

[TABLE 11.3: Suggested Financing and Payment Options for Gene Therapies 130](#_Toc2509774)

[TABLE 12.1: Expenditure Categories in Cell Manufacturing 131](#_Toc2509775)

[TABLE 12.2: The Impact of Head Count on Labor Cost 132](#_Toc2509776)

[TABLE 12.3: Cost of Manufacture in a Partially-Automated Facility 133](#_Toc2509777)

[TABLE 12.4: Cost of Manufacture in a Fully-Automated Facility 134](#_Toc2509778)

[TABLE 12.5: Companies with In-House Gene Therapy Manufacturing Capability 136](#_Toc2509779)

[TABLE 12.6: External Gene Therapy Manufacturing 137](#_Toc2509780)

[TABLE 12.7: Manufacturing Capacity in North America 138](#_Toc2509781)

[TABLE 12.8: Manufacturing Capacity in Europe 139](#_Toc2509782)

[TABLE 13.1: Select CDMOs 142](#_Toc2509785)

[TABLE 13.2: Appropriate Phase for Outsourcing 143](#_Toc2509786)

[TABLE 13.3: Important Points Considered While Fixing a CDMO 144](#_Toc2509787)

[TABLE 13.4: Share of In-House and Outsourcing 145](#_Toc2509788)

[TABLE 14.1: Global Market for Gene Therapy Products, 2018-2025 148](#_Toc2509789)

[TABLE 14.2: Global Market for Gene Therapy by Product Category, 2018-2025 150](#_Toc2509790)

[TABLE 14.3: Competitive Landscape in Gene-Modified Cell Therapy Products 151](#_Toc2509791)

[TABLE 14.4: Estimated Sales of Top Ten Clinical-Stage Gene Therapy Projects 152](#_Toc2509792)

[TABLE 14.4: (CONTINUED) 153](#_Toc2509793)

[TABLE 14.5: Vector and Plasmid DNA Manufacturing Market by Geography, 2018-2025 154](#_Toc2509794)

[TABLE 14.6: Top Nine Assets of Gene Therapies between 2018 and 2024 155](#_Toc2509795)

[TABLE 14.7: Net Present Value (NPV) of Select Gene Therapy Product Candidates 157](#_Toc2509796)

[TABLE 14.8: Net Present Value (NPV) of Yescarta and Kymriah 158](#_Toc2509797)

[TABLE 15.1: 4D Molecular Therapeutics’ Product Pipeline 160](#_Toc2509798)

[TABLE 15.2: Abeona’s Product Pipeline 161](#_Toc2509799)

[TABLE 15.3: Adaptimmune’s Pipeline Programs 162](#_Toc2509800)

[TABLE 15.4: Allogene Therapeutics’ Pipeline of Product Candidates 170](#_Toc2509801)

[TABLE 15.5: Amicus’ Gene Therapy Pipeline 174](#_Toc2509802)

[TABLE 15.6: AskBio’s Therapeutic Pipeline 175](#_Toc2509803)

[TABLE 15.7: Audentes’ Product Candidates 177](#_Toc2509804)

[TABLE 15.8: AVROBIO’s Gene Therapy Programs 180](#_Toc2509805)

[TABLE 15.9: Benitec’s Product Pipeline using Gene Silencing Technologies 181](#_Toc2509806)

[TABLE 15.10: Bioverativ’s Product Pipeline 182](#_Toc2509807)

[TABLE 15.11: bluebird bio’s Product Pipeline 184](#_Toc2509808)

[TABLE 15.12: CARsgen Therapeutics’ Product Candidates 189](#_Toc2509809)

[TABLE 15.13: Casebia’s Pipeline at a Glance 190](#_Toc2509810)

[TABLE 15.14: Celyad’s Program Status at a Glance 191](#_Toc2509811)

[TABLE 15.15: CRISPR Therapeutics’ Clinical Programs 194](#_Toc2509812)

[TABLE 15.16: Editas’ Diverse Product Pipeline 197](#_Toc2509813)

[TABLE 15.17: Elixirgen’s Pipeline for Genetic and Age-Related Diseases 198](#_Toc2509814)

[TABLE 15.18: Fibrocell’s Personalized Biologics Pipeline 199](#_Toc2509815)

[TABLE 15.19: Freeline’s Pipeline of Gene Therapy Treatments in Development 201](#_Toc2509816)

[TABLE 15.20: Gemini’s Pipeline 202](#_Toc2509817)

[TABLE 15.21: Genethon’s Products in Development 204](#_Toc2509818)

[TABLE 15.22: Horama’s Product Pipeline 207](#_Toc2509819)

[TABLE 15.23: Intellia’s in vivo and ex vivo RD Pipeline 208](#_Toc2509820)

[TABLE 15.24: Kite’s CAR-T Pipeline 209](#_Toc2509821)

[TABLE 15.25: Kolon’s Gene Therapeutics in Development 210](#_Toc2509822)

[TABLE 15.26: Krystal Biotech’s P[peline Programs for Orphan Skin Diseases 211](#_Toc2509823)

[TABLE 15.27: Meira’s Pipeline 216](#_Toc2509824)

[TABLE 15.28: MolMed’s Product Candidates 220](#_Toc2509825)

[TABLE 15.29: Mustang Bio’s Product Pipeline 221](#_Toc2509826)

[TABLE 15.30: Myonexus’ Clinical Stage LGMD Gene Therapy Pipeline 224](#_Toc2509827)

[TABLE 15.31: Nightstar Therapeutics’ Pipeline Programs 225](#_Toc2509828)

[TABLE 15.32: Orchard Therapeutics’ Pipeline 229](#_Toc2509829)

[TABLE 15.33: Oxford BioMedica’s Proprietary Product Pipeline 230](#_Toc2509830)

[TABLE 15.34: Oxford BioMedica’s Partnered Products 231](#_Toc2509831)

[TABLE 15.35: Oxford BioMedica’s IP-Enabled Royalty-Bearing Products 231](#_Toc2509832)

[TABLE 15.36: Posedia’s Product Pipeline 234](#_Toc2509833)

[TABLE 15.37: PTC’s Gene Therapy Programs for CNS Disorders 237](#_Toc2509834)

[TABLE 15.38: REGENXBIO’S Product Pipeline 241](#_Toc2509835)

[TABLE 15.39: REGENXBIO’S & Licensees’ Pipeline 242](#_Toc2509836)

[TABLE 15.40: Sangamo’s Proprietary Programs 244](#_Toc2509837)

[TABLE 15.41: Sangamo’s Programs for Partners 244](#_Toc2509838)

[TABLE 15.42: Sarepta’s Huge Product Pipeline 246](#_Toc2509839)

[TABLE 15.43: Spark Therapeutics’ Pipeline 251](#_Toc2509840)

[TABLE 15.44: Translate Bio’s Lead Product Candidates 255](#_Toc2509841)

[TABLE 15.45: uniQure’s Product Pipeline 257](#_Toc2509842)

[TABLE 15.46: Vybion’s Drug Pipeline 258](#_Toc2509843)

About BioInformant:

As the first and only market research firm to specialize in the Regenerative Medicine (RM) industry, BioInformant research has been cited by the Wall Street Journal, Nature Biotechnology, Xconomy, and Vogue Magazine.

Serving Fortune 500 companies that include Pfizer, GE Healthcare, and Goldman Sachs, BioInformant is your global leader in stem cell industry data.

To learn more, visit BioInformant.com.

**BioInformant Worldwide, LLC**

**www.BioInformant.com**